Final Up to date on January 26, 2023 by GlobeNewsWire
BOSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) — LAPIX Therapeutics, Inc. (“LAPIX”), a biopharma firm centered on growing novel, orally bioavailable immune system restoration therapies for autoimmune ailments and oncology, as we speak introduced the profitable final result of its pre-IND assembly request with the U.S. Meals and Drug Administration (FDA). The assembly’s goal was to realize alignment with the FDA on LAPIX’s IND-enabling plan for its novel, first-in-class, immune tolerance restoration small molecule, LPX-TI641, below growth for neuro-autoimmune indications comparable to a number of sclerosis (MS), Neuromyelitis Optica Spectrum Problems (NMOSD), and Myelin Oligodendrocyte Glycoprotein Antibody Illness (MOGAD).
LAPIX’s pre-IND drug candidate, LPX-TI641, is an orally bioavailable, antigen-agnostic, immune tolerance restoration small molecule that may restore the regulatory T cell/T helper sort 17 cell (Treg/Th17) imbalance related to autoimmune ailments comparable to MS. LPX-TI641 is supported by a strong physique of preclinical information and has proven a good security profile and superior efficacy to present requirements of care in a number of non-clinical, experimental autoimmune encephalomyelitis (EAE) fashions of MS.
“As a high-efficacy, non-immune suppressive compound with a projected favorable security profile, LPX-TI641 is predicted to fill a transparent unmet want within the present MS therapy panorama. We additionally anticipate it to be secure sufficient for early and long-term use,” mentioned Anas M. Fathallah, Ph.D., President, and Co-founder of LAPIX. “The end result of this assembly request helps LAPIX’s IND-enabling plan and we now have a path ahead to the clinic.”
About LAPIX Therapeutics
LAPIX Therapeutics Inc. is a Boston, MA-based firm within the biopharma sector, centered on growing novel, orally bioavailable immune system restoration therapies, together with immune tolerance restoration remedy for autoimmune ailments, immune tolerance induction therapies for gene remedy and enzyme substitute remedy, and immune perform restoration therapies for oncology. To be taught extra, go to lapixtherapeutics.com or comply with us on LinkedIn.
